TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study

Abstract

Background Breast cancer chemoresistance is attributed to a wide variety of mechanisms, including autophagy. Transcription factor EB (TFEB) has been recently identified and characterized as one major regulator of autophagy and lysosomal genesis. Objective This study aims to evaluate the prognostic impact of TFEB and its pathway in breast cancer chemoresistance. Methods This retrospective study analyzes the expression of TFEB, CARM1, SIRT1, and Beclin-1 and the methylation of PITX2 in breast carcinoma. A group of breast cancer patients treated with chemotherapy, who relapsed within 12 months from treatment initiation, were compared to a sub-cohort of chemo-treated patients who did not recur within 12 months of follow-up. The expression of TFEB, CARM1, SIRT1, and Belcin-1 was analyzed using immunohistochemistry or RT-PCR on formalin-fixed paraffin-embedded samples. PITX2 methylation was tested with the diagnostic CE-marked kit Therascreen PITX2 RGQ PCR. In the final model, 136 cases of chemo-treated breast cancer were included. Results A higher TFEB and Beclin-1 expression correlate with shorter survival in patients with chemo-treated invasive breast cancer (respectively HR 3.46, CI.95 1.27–9.47, p < 0.05 and 7.11, CI.95 2.54–19.9). TFEB, CARM1, and SIRT1 are positively correlated with Beclin-1. The protein expression of SIRT1 is significantly associated with TFEB and CARM1 so that a very low SIRT1 expression (lower than the first quartile of the H-score distribution) correlates with a low expression of TFEB and CARM1 and with longer survival. SIRT1 seems to have a lower H-score in the basal-like and HER2-enriched tumors than the luminal subtypes. Beclin-1 and TFEB seem to have a higher H-score in the basal-like and HER2-enriched tumors than the luminal subtypes. PITX2 methylation analysis was feasible only in 65% of the selected samples, but no significant differences between cases and controls were found, and there was also no correlation with the expression of the TFEB pathway. Conclusions TFEB, SIRT1, and Beclin-1 seem to have a potential prognostic significance in patients with chemo-treated breast cancer, likely because of their role in the regulation of autophagy. In addition, no correlation between TFEB and PITX2 methylation was found, likely because they perform two different roles within the autophagy process.

Systematic analysis of cancer‐specific synthetic lethal interactions provides insight into personalized anticancer therapy

“…Of these, many genes were detected to play roles in two to six hallmarks, especially HIF1A and SIRT1 , which were found in six hallmarks of cancer. Indeed, both of these genes have been reported to play roles in tumorigenesis [28–30], implicating their potential as drug targets for cancer therapy. Furthermore, 762 genes (7.34%) were identified as cancer genes according to annotations in OncoKB [31], including 227 oncogenes and 237 tumour suppressor genes (TSGs) (Fig.…”

MicroRNA-141-3p reduces pulmonary hypoxia/reoxygenation injury through suppression of Beclin-1-dependent autophagy

“…In addition, forced SIRT1 expression could partially negate the protective role of miR-204 on H/R-induced apoptosis and autophagy [ 42 ]. SIRT1 expression was found to correlate positively with Beclin-1 [ 43 ], and SIRT1 can contribute to autophagy via deacetylation of Beclin-1 [ 44 ]. Our study revealed that overexpression of SIRT1 could increase autophagy and apoptosis in PMVECs by promoting the deacetylation of Beclin-1.…”

A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer

“…For example, the treatment goal of stage I to III breast cancer is a cure, and the prognosis is relatively good [145]. However, a study reported that in early breast cancer, cases of TFEB overexpression and high lysosomal biogenesis tend to be associated with poor postoperative outcomes and a poor prognosis [105,146]. Interestingly, other reports showed that overexpression of TFEB in TAMs in the breast cancer microenvironment greatly ameliorated the tumor-promoting gene expression profile of the TAMs (details are explained below) [89], which shows that TFEB plays different roles in different components of the tumor microenvironment at the same time, raising new questions with regard to the targeting TFEB.…”